Idexx Laboratories (IDXX) risk factors, FY2024 10-K

Idexx Laboratories's FY2024 10-K, filed Feb 21, 2025, lists 13 risk factors in 3 groups. There is no earlier 10-K to compare against, so the most company-specific risks are listed below.

Open IDXX in Gloom →
Idexx Laboratories' chart, financials and news, free in your browser.Open IDXX in Gloom →
Risk factors listed
133 groups
Section length
13k wordsItem 1A

Idexx Laboratories's biggest risks in the FY2024 10-K

  • IDEXX faces manufacturing complexities in biologic diagnostics like rapid assays and water products.
  • Artificial intelligence integration creates potential reputational and liability risks for product offerings.
  • International distributor dependency and U.S. dollar strength impacting 35% of revenue create operational pressures.

The risks most specific to Idexx Laboratories

  • RISKS RELATED TO OUR BUSINESS AND INDUSTRY

    Our biologic products are complex and difficult to manufacture, which could negatively affect our ability to supply our customers

    Manufacturing biologic rapid assay, livestock, poultry, water, and dairy products is complex due to inherent variability in biological materials like antibodies and cells.

  • RISKS RELATED TO OUR BUSINESS AND INDUSTRY

    Issues in the use of AI in our product offerings may result in reputational harm or liability

    Integrating artificial intelligence into devices and cloud applications risks reputational harm and liability.

  • RISKS RELATED TO OUR BUSINESS AND INDUSTRY

    Our success is heavily dependent on our continued differentiated product and service innovation

    Success relies heavily on continuously innovating differentiated products and incorporating artificial intelligence, machine learning, and automation.

  • RISKS RELATED TO OUR BUSINESS AND INDUSTRY

    Changes in testing patterns could negatively affect our operating results

    Diagnostic test demand for companion animals and livestock could decline if new vaccines or disease preventatives gain broad market acceptance.

  • RISKS RELATED TO OUR BUSINESS AND INDUSTRY

    We sell many products through distributors, which presents risks that could negatively affect our operating results

    International sales depend on third-party distributors who may promote competing products over IDEXX offerings.

  • GENERAL RISKS

    Strengthening of the rate of exchange for the U.S. dollar has a negative effect on our business

    Foreign exchange rate strengthening for the U.S. dollar negatively impacts the 35% of revenue generated outside the U.S. in 2024.

All 13 risk factors

Headings as the filing states them, in filing order.

RISKS RELATED TO OUR BUSINESS AND INDUSTRY

  1. 01Our biologic products are complex and difficult to manufacture, which could negatively affect our ability to supply our customers
  2. 02Issues in the use of AI in our product offerings may result in reputational harm or liability
  3. 03Our success is heavily dependent on our continued differentiated product and service innovation
  4. 04Increased competition from and technological advances by our competitors could negatively affect our operating results
  5. 05Changes in testing patterns could negatively affect our operating results
  6. 06We sell many products through distributors, which presents risks that could negatively affect our operating results

GENERAL RISKS

  1. 07We depend on the efforts of key personnel and talent to succeed and compete effectively
  2. 08Factors and events beyond our control could disrupt our operations, supply chain, and logistics network and adversely affect our business
  3. 09technology, market risk and reputational risk) and social and human effects (such as harm to health and well-being) associated with climate change. These risks can be either acute (short-term) or chronic (long-term)
  4. 10could cause a decline in demand for our products and services. These disruptions could also cause economic slowdowns or increased economic uncertainty
  5. 11Strengthening of the rate of exchange for the U.S. dollar has a negative effect on our business

RISKS RELATED TO AN INVESTMENT IN OUR SECURITIES

  1. 12Fluctuations in our quarterly or annual results may cause our stock price to decline
  2. 13The market price of our common stock may be highly volatile, and you may not be able to resell your shares at or above the price you paid

Other Idexx Laboratories 10-Ks

  • FY2025 10-K risk factors
    24 risks8 reworded

    AI use now extends internally to coding, product development, operational efficiency, innovation, and customer value.

    Filed Feb 20, 2026

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.